Late relapse after a sustained virologic response at 24 weeks after treatment with daclatasvir and asunaprevir combination therapy for chronic hepatitis c virus genotype 1b infection with liver cirrhosis

Internal Medicine

Volumn 57, Issue 7, 2018, Pages 951-956

  Uojima, Haruki ^a   Murakami, Shuko ^b   Nakatani, Seigo ^a   Hidaka, Hisashi ^a   Takeuchi, Atsuko ^a   Tanaka, Yoshiaki ^a   Inoue, Tomoyoshi ^a   Yamane, Keiko ^a   Kubota, Kousuke ^a   Nakazawa, Takahide ^a   Shibuya, Akitaka ^a   Tanaka, Yasuhito ^b   Koizumi, Wasaburo ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Asunaprevir; Daclatasvir; Interferon free regimen; Late relapse; Liver cirrhosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASUNAPREVIR; DACLATASVIR; RNA; ANTIVIRUS AGENT; BMS-790052; IMIDAZOLE DERIVATIVE; INTERFERON; ISOQUINOLINE DERIVATIVE; SULFONAMIDE; VIRUS RNA;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD ANALYSIS; BRAIN DISEASE; CASE REPORT; CHRONIC HEPATITIS C; CLINICAL ARTICLE; DRUG WITHDRAWAL; DYNAMIC CONTRAST-ENHANCED MAGNETIC RESONANCE IMAGING; FEMALE; GENE SEQUENCE; GENETIC VARIABILITY; HEPATITIS C VIRUS GENOTYPE 1B INFECTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTRANSAMINASEMIA; LIMIT OF QUANTITATION; LIVER BIOPSY; LIVER CELL; LIVER CIRRHOSIS; NEVUS FLAMMEUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; PHYSICAL EXAMINATION; POLYMERASE CHAIN REACTION; PORTAL HYPERTENSION; PRESSURE GRADIENT; RELAPSE; RNA ANALYSIS; RNA EXTRACTION; SPLENOMEGALY; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; TREATMENT OUTCOME; VEIN CATHETERIZATION; VIRUS LOAD; WILD TYPE; AMINO ACID SEQUENCE; COMBINATION DRUG THERAPY; COMPLICATION; GENETICS; GENOTYPE; HEPACIVIRUS; ISOLATION AND PURIFICATION; RECURRENT DISEASE; SEQUENCE HOMOLOGY; VIROLOGY;

AGED; AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; INTERFERONS; ISOQUINOLINES; LIVER CIRRHOSIS; PHYLOGENY; POLYMERASE CHAIN REACTION; RECURRENCE; RNA, VIRAL; SEQUENCE HOMOLOGY, AMINO ACID; SULFONAMIDES; SUSTAINED VIROLOGIC RESPONSE;

EID: 85044711569     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.9671-17     Document Type: Article

References (17)

1. El-Serag HB, Kanwal F, Richardson P, Kramer J. Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology 64: 130-137, 2016.
2. Holmes JA, Thompson AJ. Interferon-free combination therapies for the treatment of hepatitis C: current insights. Hepat Med 7: 51-70, 2015.
3. Formann E, Steindl-Munda P, Hofer H, et al. Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy. Aliment Pharmacol Ther 23: 507-511, 2006.
4. Simmons B, Saleem J, Hill A, Riley RD, Cooke GS. Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis. Clin Infect Dis 62: 683-694, 2016.
5. Colson P, Bregigeon S, Tourres C, Solas C, Poizot-Martin I, Tamalet C. Relapse of hepatitis C virus after 14 months of sustained virological response following pegylated-interferon alpha plus ribavirin therapy in a human immunodeficiency virus type 1 infected patient. J Clin Virol 58: 309-314, 2013.
6. de Franchis R; Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol 63: 743-752, 2015.
7. Lawitz E, Poordad F, Kowdley KV, et al. A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1. J Hepatol 59: 18-23, 2013.
8. Simmons B, Saleem J, Hill A, Riley RD, Cooke GS. Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis. Clin Infect Dis 62: 683-694, 2016.
9. Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 378: 571-583, 2011.
10. Li QR, Zhang CJ, Xiong YL, et al. Long-term assessment of relapse and associated risk factors in chronic hepatitis C patients treated with interferon and ribavirin. Zhonghua Gan Zang Bing Za Zhi 20: 353-356, 2012 (in Chinese, Abstract in English).
11. Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 59: 2083-2091, 2014.
12. Kumada H, Suzuki F, Suzuki Y, et al. Randomized comparison of daclatasvir + asunaprevir versus telaprevir + peginterferon/ribavirin in Japanese hepatitis C virus patients. J Gastroenterol Hepatol 31: 14-22, 2016.
13. Ascher DB, Wielens J, Nero TL, et al. Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA. Sci Rep 4: 4765, 2014.
14. Garimella T, Wang R, Luo WL, et al. Single-dose pharmacokinetics and safety of daclatasvir in subjects with renal function impairment. Antivir Ther 20: 535-543, 2015.
15. Rutter K, Hofer H, Beinhardt S, et al. Durability of SVR in chronic hepatitis C patients treated with peginterferon-α2a/ribavi-rin in combination with a direct-acting anti-viral. Aliment Pharmacol Ther 38: 118-123, 2013.
16. Soriano V, Vispo E, de Mendoza C, et al. Very late relapse after discontinuation of antiviral therapy for chronic hepatitis C. Antivir Ther 18: 1033-1035, 2013.
17. González-Reimers E, Quintero-Platt G, Martín-González C, Pérez-Hernández O, Romero-Acevedo L, Santolaria-Fernández F. Thrombin activation and liver inflammation in advanced hepatitis C virus infection. World J Gastroenterol 22: 4427-4437, 2016.